Jupiter Life Line Hospitals share price today

Jupiter Life Line Hospitals Ltd's share price was ₹287.60 at the close on 6 November 2026. It has been falling for 2 weeks. That is 4.0% above its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 7 weeks running.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Jupiter Life Line Hospitals Ltd is in stage 4. The phase helps read everything below.

In the last 52 weeks it traded between ₹242 and ₹332, and at that close it sat 51% of the way up from that low.

Over the last 3.1 years the share price moved +35% while the NIFTY 500 moved +26%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Two changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) and highest quarterly revenue in 16 quarters.

1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare)

   In the September 2026 quarter revenue was ₹456 crore, +15.7% on a year earlier.

2. Highest quarterly revenue in 16 quarters

   Revenue of ₹456 crore in the September 2026 quarter is the highest of the last 16 quarters.

For July to September 2026 (the quarter ended 30 September 2026), Jupiter Life Line Hospitals reported revenue of ₹456 crore, up 15.7% from ₹394 crore a year earlier, and a profit of ₹56.0 crore, down 1.8% from ₹57.0 crore.

Jupiter Life Line Hospitals results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 18 May 2026, about January to March 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Jupiter Life Line Hospitals closed at ₹287.60 on 6 November 2026, down 7.3% from ₹310.38 a year earlier (7 November 2025) and up 41.2% over three years. Its highest weekly close since September 2023 was ₹331.50 on 31 July 2026.

Jupiter Life Line Hospitals share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 6 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

169 weekly closes from 22 September 2023 to 6 November 2026.

6 Nov 2026: Jupiter Life Line Hospitals closed at ₹287.60, up 11.8% on the week and up 12.5% on the month. Results for July to September 2026: Revenue up 15.7% and profit down 1.8% on a year earlier.

Earlier

• 24 Jul 2026: Share split: face value cut from ₹10 to ₹2 a share (ex-date).
• 22 May 2026: ex-date for an interim dividend of ₹1 a share.
• 18 May 2026: Jupiter Life Line Hospitals held its results call for January to March 2026. Management guided: Dombivli operating profit burn ₹2-3 crore per month average, operating profit breakeven end two years of operations (CY28 end, January to March 2028)

Jupiter Life Line Hospitals paid ₹0.20 a share in regular dividends in the 12 months to 7 November 2026 (1 payment), a yield of 0.07% at the ₹287.60 close on 6 November 2026. The last was an interim dividend of ₹1 a share, ex-date 22 May 2026.

Jupiter Life Line Hospitals dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 1 of the last 12 months' payments came before a split or bonus; the 12-month total above is on today’s share count.

Yes. Jupiter Life Line Hospitals Ltd paid out 3% of its profit as dividends in FY26, and it paid a dividend in 3 of its last 7 reported years.

From the NSE corporate-actions record, read 7 November 2026.

On the call for January to March 2026, held on 18 May 2026, Jupiter Life Line Hospitals' management guided: Dombivli operating profit burn ₹2-3 crore per month average, operating profit breakeven end two years of operations (CY28 end, January to March 2028)

“With BKC in the pipeline, we are looking at approximately 1,700 new beds in this expansion cycle, taking our long-term capacity to nearly 3,000 beds - that is a network we believe will be genuinely differentiated and will cement our position as the leading hospital group in Western India”Dr. Ankit Thakker, on the call for January to March 2026

What management guided

• Pune South opening CY28; Mira Road excavation begin end CY26 on completion of regulatory clearances.
• Thane hospital expansion final regulatory approvals expected sometime in FY27; exact scope to be determined post clearance.
• Indore next phase 111 beds contingent on occupancy crossing 60.0% threshold.
• Base business growth: Thane inflation-linked only (at capacity); Pune inflation plus occupancy gains; Indore case mix plus occupancy plus inflation.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for January to March 2026, 18 May 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

When Jupiter Life Line Hospitals reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Dombivli July to September 2026 occupancy ramp rate and insurance empanelment progress - two months operations insufficient for meaningful trajectory per management; Q2 data expected to provide >100 bed occupancy confirmation and insurance timeline clarity.

Jupiter Life Line Hospitals is not on any of our India lists this week.

Jupiter Life Line Hospitals Ltd earned ₹56.0 Cr of net profit in the Sep 2026 quarter, −1.8% on the same quarter a year earlier. Full-year FY26 profit was ₹194 Cr. Over 6 years profit has grown 36.5% a year on average. That is 12.3% of the quarter's revenue. The same quarter a year earlier earned ₹57.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹194 Cr (+0.0% on the year before).

Why profit moved: revenue changed +15.7% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed −5.9% and revenue +14.2%. Profit is growing slower than sales: rising costs are taking part of the growth.

Jupiter Life Line Hospitals Ltd reported ₹456 Cr of revenue in the Sep 2026 quarter, +15.7% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 6 years it has grown 21.6% a year on average. The last full year, FY26, came in at ₹1,500 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹1,620 Cr.

FY26 revenue was ₹1,500 Cr, +15.2% on the year before.

Recent pace: the last four quarters grew +14.2% on average, against 21.6% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +14.3%, against +16.8% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −6.1%, against +0.0% a year (rolling over).

Jupiter Life Line Hospitals Ltd's operating margin was 23.0% in the Sep 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 7 years it has been between 14.0% and 23.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.0 percentage points on the year while gross margin changed −0.2 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 3 years, 115% of Jupiter Life Line Hospitals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹268 Cr of operating cash against ₹194 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹438 Cr of spending on assets, free cash was −₹170 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 115% of profit came in as cash: the cash cycle got 98 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 5.1× depreciation over three years. The next section checks what that spending is building.

Jupiter Life Line Hospitals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −54 days in FY26, up from −152 days in FY21. It spent ₹951 Cr on assets over the last 3 years. Customers take 18 days to pay, and stock sits for 49 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹1,500 Cr, each day of that cycle ties up about ₹4.1 Cr, so roughly −₹222 Cr is tied up in the business at any time.

FY26: customers took 18 days to pay and stock sat for 49 days, about 1.6 months of sales sitting as stock, for a full cycle of −54 days, longer than FY21's −152.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 49 days. Customers pay about 18 days after that. Suppliers are paid at 121 days. Together that makes the −54-day cycle.

Spending on assets: ₹951 Cr over the last 3 years, against ₹187 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹129 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Jupiter Life Line Hospitals Ltd's P/E is 49.7×, in the middle of its own history: higher than 43% of past readings. Its usual P/E (the middle reading) is 50.5×, over 3.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹5.68.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.

Why the multiple is where it is: over the past year earnings per share moved +0.5% while the price moved −7.3%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 3 years the price moved +12.2% a year; about +36.8% a year came from earnings growth and about −24.6 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

Jupiter Life Line Hospitals Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −6.1% in the latest quarter, against +142.5% at its best in 12 quarters, with ROCE falling at 14.2%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Jupiter Life Line Hospitals Ltd earned a ROCE of 15% in FY26. That is up from a low of 7% in FY21. Its return on capital used (ROIC) is 0.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

It comes from a 12.9% net margin and 0.63× asset turnover (sales divided by assets).

Why the return is what it is (FY26): a 12.9% net margin × 0.63× asset turnover × 1.53× leverage (assets divided by equity) ≈ 12.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 11.2% − 12.0% = −0.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The 11.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 14.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Jupiter Life Line Hospitals Ltd has total debt of ₹669 Cr against shareholder equity of ₹1,631 Cr as of Sep 2026, so its debt is 0.41× its equity. Year by year, that ratio went from 1.29 in FY23 to 0.38 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Domestic institutions raised their stake in Jupiter Life Line Hospitals Ltd by 5.7 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 19.1% of the company. Foreign institutions moved +0.3 points over the same period, to 9.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Domestic institutions: +5.7 points over 8 quarters, to 19.1%; Foreign institutions: +0.3 points over 8 quarters, to 9.1%; Promoters: +0.0 points over 8 quarters, to 40.9%.

Why the owners changed: domestic institutions drove it (+5.7 points). They raised their stake step by step.

For Jupiter Life Line Hospitals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

32.9 out of 100, rank 17 of 20 in Hospitals, with 100% of the evidence available.

Jupiter Life Line Hospitals Ltd scores 32.9 out of 100 against the 20 companies it is compared with in Hospitals, ranking 17. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 9.1 + 11.2 + 8.5 + 4.1 = 32.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Jupiter Life Line Hospitals ranks 17 of 20 Hospitals companies on the 4-Factor Sector Score, with 32.9 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Hospitals, all 20 compared on one page.

Jupiter Life Line Hospitals is the 12th largest of 20 Hospitals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Rainbow Childrens Medicare, Yatharth Hospital & Trauma Care Services and Healthcare Global Enterprises. Just below it: Kovai Medical Center & Hospital, Artemis Medicare Services and Indraprastha Medical Corporation.

Hospitals companies close in size

9. Rainbow Childrens Medicare Ltd ₹12,378 crore
10. Yatharth Hospital & Trauma Care Services Ltd ₹9,902 crore
11. Healthcare Global Enterprises Ltd ₹8,742 crore
12. Jupiter Life Line Hospitals Ltd ₹8,430 crore
13. Kovai Medical Center & Hospital Ltd ₹6,363 crore
14. Artemis Medicare Services Ltd ₹4,642 crore
15. Indraprastha Medical Corporation Ltd ₹2,802 crore

All 20 Hospitals companies, largest first

Companies close in size in other industries

635. Finolex Industries Ltd ₹8,510 crore · Building Materials - Plastic Pipes
636. Jayaswal Neco Industries Ltd ₹8,454 crore · Mining/Minerals - Iron Ore
637. Jupiter Life Line Hospitals Ltd ₹8,430 crore
638. AAVAS Financiers Ltd ₹8,428 crore · Finance - Housing
639. Aarti Pharmalabs Ltd ₹8,416 crore · Pharma - API

Sector Alpha, written by code from the published numbers. Data as of 6 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.